BCI
NBIX icon

Brinker Capital Investments’s Neurocrine Biosciences NBIX Stock Holding History

Brinker Capital Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.54M Buy
26,926
+1,785
+7% +$265K 0.03% 418
2026
Q1 		$3.31M Sell
25,141
-4,528
-15% -$601K 0.03% 520
2025
Q4 		$4.21M Sell
29,669
-1,008
-3% -$146K 0.03% 498
2025
Q3 		$4.31M Sell
30,677
-1,267
-4% -$172K 0.03% 480
2025
Q2 		$4.02M Buy
31,944
+4,426
+16% +$508K 0.03% 468
2025
Q1 		$3.04M Buy
27,518
+1,615
+6% +$205K 0.03% 525
2024
Q4 		$3.54M Sell
25,903
-1,031
-4% -$128K 0.04% 435
2024
Q3 		$3.1M Sell
26,934
-221
-0.8% -$30.3K 0.03% 487
2024
Q2 		$3.74M Sell
27,155
-1,810
-6% -$248K 0.04% 399
2024
Q1 		$3.99M Sell
28,965
-490
-2% -$66.9K 0.04% 379
2023
Q4 		$3.95M Sell
29,455
-2,749
-9% -$316K 0.05% 365
2023
Q3 		$3.62M Buy
32,204
+3,993
+14% +$420K 0.04% 381
2023
Q2 		$15.3M Sell
28,211
-3,559
-11% -$348K 0.16% 125
2023
Q1 		$3.22M Sell
31,770
-1,102
-3% -$115K 0.04% 403
2022
Q4 		$3.93M Sell
32,872
-2,288
-7% -$268K 0.08% 253
2022
Q3 		$3.73M Buy
35,160
+1,587
+5% +$161K 0.08% 252
2022
Q2 		$3.27M Buy
33,573
+99
+0.3% +$9.14K 0.06% 301
2022
Q1 		$3.14M Buy
33,474
+6,434
+24% +$545K 0.05% 370
2021
Q4 		$2.3M Sell
27,040
-4,827
-15% -$444K 0.03% 520
2021
Q3 		$3.1M Hold
31,867
– – 0.05% 404
2021
Q2 		$3.1M Buy
31,867
+20,789
+188% +$1.99M 0.04% 461
2021
Q1 		$1.08M Sell
11,078
-43,886
-80% -$4.6M 0.02% 687
2020
Q4 		$5.27M Buy
54,964
+29,579
+117% +$2.86M 0.08% 297
2020
Q3 		$2.44M Buy
+25,385
New +$2.94M 0.04% 407

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brinker Capital Investments's NBIX Position: Q2 2026 in Review

Brinker Capital Investments increased its Neurocrine Biosciences (NBIX) stake by 7.1% in Q2 2026, buying an estimated $265K and bringing the position to 26,926 shares worth $4.54M. The position accounts for 0.03% of the portfolio, ranked #418.

Brinker Capital Investments first reported a position in NBIX in Q3 2020 and has held it in 24 quarters since. The position peaked at $15.3M in Q2 2023. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Brinker Capital Investments held 26,926 shares of Neurocrine Biosciences worth $4.54M as of Q2 2026.
  • Brinker Capital Investments bought 1,785 Neurocrine Biosciences shares in Q2 2026, an estimated $265K.
  • Neurocrine Biosciences made up 0.03% of Brinker Capital Investments's portfolio in Q2 2026, its #418 holding.
  • Brinker Capital Investments first reported a position in Neurocrine Biosciences in Q3 2020 and has held it in 24 quarters since.
  • Brinker Capital Investments's Neurocrine Biosciences position peaked at $15.3M in Q2 2023.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.